Edgewise Therapeutics Reports Improvements In Heart Drug Trial

Benzinga06-17

Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial. Patients received doses ranging from 25 mg to 150 mg. EDG-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644795548?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=260,format=auto,quality=85/files/images/story/2026/06/16/Vital-Signs-Monitor-Screen-Showing-Heart.jpeg","is_english":true,"pubTime":"2026-06-17 01:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644795548","market":"us","top_or_hot":-1,"title":"Edgewise Therapeutics Reports Improvements In Heart Drug Trial","media":"Benzinga","content":"<div>\n<p>Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.\nPatients received doses ranging from 25 mg to 150 mg.\nEDG-...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/06/53233008/edgewise-therapeutics-reports-improvements-in-heart-drug-trial\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics Reports Improvements In Heart Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics Reports Improvements In Heart Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-17 01:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/06/53233008/edgewise-therapeutics-reports-improvements-in-heart-drug-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.\nPatients received doses ranging from 25 mg to 150 mg.\nEDG-...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/06/53233008/edgewise-therapeutics-reports-improvements-in-heart-drug-trial\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4531","symbol_name":"中概回港概念","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/06/53233008/edgewise-therapeutics-reports-improvements-in-heart-drug-trial","article_id":"2644795548","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=260,format=auto,quality=85/files/images/story/2026/06/16/Vital-Signs-Monitor-Screen-Showing-Heart.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/06/53233008/edgewise-therapeutics-reports-improvements-in-heart-drug-trial","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644795548","pubTimestamp":1781631600,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4531":"中概回港概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4539":"次新股","EWTX":"Edgewise Therapeutics, Inc.","HCM":"和黄医药","BK4007":"制药"},"translate_title":"Edgewise Therapeutics报告心脏药物试验取得进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1,"EWTX":1.5},"content_text":"Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.\nPatients received doses ranging from 25 mg to 150 mg.\nEDG-7500 demonstrated clinically meaningful improvements in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM).\nHCM is a genetic heart condition where the heart muscle thickens, making it harder for the heart to pump blood and potentially leading to complications like heart failure or sudden cardiac death.\nThe company said the oral cardiac sarcomere modulator improved key measures of heart function, symptoms, and biomarkers without compromising systolic function.\nThe Part D cohort enrolled 53 patients, including 20 with obstructive HCM (oHCM) and 33 with nonobstructive HCM (nHCM). The 12-week study was designed to help inform a future Phase 3 trial.\nAmong oHCM patients, EDG-7500 produced significant reductions in left ventricular outflow tract gradient (LVOT-G) at rest and after the Valsalva maneuver.\nAccording to the company, 90% of patients showed improvement in hemodynamic measures.\nThe treatment also reduced heart failure severity markers. Nearly three-quarters of oHCM patients either achieved normal NT-proBNP levels or recorded at least a 50% reduction from baseline.\nPatient-reported outcomes improved as well. Additionally, 70% of patients improved by at least one New York Heart Association functional class.\nIn nHCM patients, EDG-7500 generated an average 65% reduction in NT-proBNP levels.\nThe company said 88% of patients achieved either normalized NT-proBNP levels or at least a 50% reduction from baseline.\nPatients also reported symptom improvements, with a 13-point mean increase and 64% achieving at least one class improvement in NYHA status.\nDiastolic function measures improved as well.\nEdgewise said EDG-7500 was generally well tolerated, with no new safety signals identified among the 53 patients evaluated. Most adverse events were mild to moderate in severity.\nThe company reported no meaningful changes in left ventricular ejection fraction and no cases where ejection fraction fell below 50%. Two cases of new-onset atrial fibrillation were reported, though investigators determined both events were unrelated to the study drug.\nJust two weeks ago, the biopharmaceutical company agreed to sell its muscular dystrophy business to Servier for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments.\nThe transaction meaningfully strengthens Edgewise’s balance sheet and sharpens the company’s strategic focus on its cardiovascular pipeline.\nEWTX Price Action: Edgewise Therapeutics shares were down 2.58% at $34.29 at the time of publication on Tuesday, according to Benzinga Pro data.\nPhoto via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644795548","isCrawlerRequest":true}